UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 297, 2025

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	EBS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02. Departure ~~Results~~of Directors or Certain Officers; Election of ~~Operations~~Directors; ~~and~~Appointment ~~Financial~~of ~~Condition~~Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~October~~November 297, 2025, Louis W. Sullivan, M.D., a director of Emergent BioSolutions Inc. (the "“Company"”), ~~issued~~notified ~~a press release (~~the ~~"Press~~Company ~~Release")~~of ~~announcing~~his ~~its~~intent ~~financial~~to ~~and~~retire ~~operating~~as ~~results~~a ~~for~~Class ~~the~~II ~~quarter~~board ~~ended~~member ~~September~~effective 30November 14, 2025. ADr. ~~copy~~Sullivan’s decision to retire is not the result of any disagreement with the ~~Press~~Company ~~Release~~on isany ~~furnished~~matter asrelated ~~Exhibit~~to 99the Company’s operations, policies or practices.1 Dr. toSullivan ~~this~~has ~~Current~~served ~~Report~~as ona ~~Form~~director ~~8-K~~since ~~(this~~June ~~"Form~~2006 ~~8-K")~~and most recently, as Chairman of the Compensation Committee and isas ~~incorporated~~a ~~herein~~member byof ~~reference.~~the Nominating and Corporate Governance Committee.

Item 7.01. Regulation FD Disclosure.

On ~~October~~November 2912, 2025, the Company ~~will~~issued ~~host~~ a ~~conference~~press ~~call~~release toregarding ~~discuss its financial and operating results for the quarter ended September 30, 2025~~Dr. ~~The~~ ~~Company will use presentation materials in connection with this conference call (the "Earnings Call Slides"), which will be posted on the Company~~Sullivan’s ~~website~~retirement, ata ~~www.emergentbiosolutions.com. A~~ copy of ~~the~~which ~~Earnings Call Slides~~ is furnished as Exhibit 99.21 to this ~~Form~~Current ~~8-K~~Report ~~and is incorporated herein by reference. Information~~ on ~~the Company's website is not, and will not be deemed to be, a part of this~~ Form 8-K ~~or incorporated into any other filings the Company may make with the U~~.S. ~~Securities and Exchange Commission.~~

The information ~~contained~~ in ~~Items~~this ~~2.02~~Item ~~and~~ 7.01 ~~of this Form 8-K~~ and ~~Exhibits~~Exhibit 99.1 ~~and 99.2 attached~~ hereto, shall not be deemed "“filed"” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ~~(the "Exchange Act")~~, ~~or otherwise be subject to the liabilities of that section,~~ nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, ~~or the Exchange Act,~~ except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press release issued by Emergent BioSolutions Inc. on ~~October~~November 2912, 2025.
99.2						Earnings Call Slides, dated October 29, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EMERGENT BIOSOLUTIONS INC.
Dated: October 29, 2025	By:	/s/ RICHARD S. LINDAHL
Dated: November 12, 2025	By:	/s/ RICHARD S. LINDAHL
		Name: Richard S. LindahlTitle: Executive Vice President, Chief Financial Officer and Treasurer

Filing Compare · Emergent BioSolutions Inc.